Search clinical trials for: Glipizide and Glargine

Total 271745 results

Emory University
Sanofi

Completed

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

Type 2 Diabetes | Inpatient Hyperglycemia

United States
Sanofi

Completed

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE)

Diabetes Mellitus, Type 2

Brazil, United States, Finland, Spain, Austria, Canada, Czech Republic, France, Greece, Ireland, Israel, Mexico, Netherlands, Russian Federation, Slovakia, Sweden, Turkey
Population Health Research Institute
Sanofi

Completed

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi (REMIT-iGL)

Type 2 Diabetes Mellitus

Canada
Hoffmann-La Roche

Terminated

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Diabetes Mellitus Type 2

China, Hong Kong, Korea, Republic of, Philippines, Taiwan, Malaysia, Thailand
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O1)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Eli Lilly and Company

Completed

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Eli Lilly and Company

Completed

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro

Diabetes Mellitus
Sanofi

Completed

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine (QoL)

Diabetes Type 2

Sweden
Inova Health Care Services

Terminated

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Sanofi

Completed

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (Lixilan-O-AP)

Type 2 Diabetes Mellitus

China, Korea, Republic of, Malaysia, Taiwan
University of Jordan

Completed

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Diabetes Mellitus, Type 2

Jordan
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia
Eli Lilly and Company

Completed

A Study for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Brazil, Canada, Mexico, India, Australia, China, Korea, Republic of
Hallym University Medical Center

Completed

Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix

Diabetes Mellitus, Type 2
Sanofi

Completed

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Diabetes Mellitus, Type 2

United States, Canada
University of Maryland, Baltimore

Completed

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

Diabetic Ketoacidosis

United States
Tehran University of Medical Sciences

Completed

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Type 2 Diabetes Mellitus

Iran, Islamic Republic of
University of the Highlands and Islands

Completed

The Acute Effects of Commercially Available Drinks on the Endothelial Function of Humans Following a High-fat Meal

Endothelial Dysfunction

United Kingdom
The Coca-Cola Company

Completed

Evaluation of a New Orange-Based Beverage Enriched With Polyphenols in Adult Humans (BIONAOS)

Obesity | Overweight

Spain
National Institute of Neurosciences and Hospital...

Completed

Insulin for Hyperglycemia in Stroke Trial

Hyperglycemia | Stroke, Acute

Bangladesh
Eli Lilly and Company

Completed

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
The Emmes Company, LLC
The Emmes Company, LLC

Completed

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

Necrotizing Enterocolitis | Intra-abdominal Infection

United States
Eli Lilly and Company

Completed

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Type 2 Diabetes

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin (OPTIMIZATION)

Diabetes Mellitus, Type 2

China
Sanofi

Completed

20 Week Bridging Study in Type II DM

Diabetes Mellitus Type II
Eli Lilly and Company

Recruiting

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

Cardiovascular Diseases | Obesity | Overweight | Type 2 Diabetes | Chronic Kidney Disease | Overweight or Obesity

United States, Italy, Spain, Korea, Republic of, India, Turkey, Austria, Puerto Rico, Mexico, Romania, Brazil, Czechia, Germany, Argentina, Greece, Slovakia
Eli Lilly and Company

Completed

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

Type 2 Diabetes Mellitus

India
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Hoffmann-La Roche

Completed

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Diabetes Mellitus Type 2

Australia, Belgium, Hong Kong, United States, Germany, Portugal, Russian Federation, France, Canada, Finland, Austria, New Zealand, Spain, Poland, Thailand, Italy, Serbia, Korea, Republic of, Hungary, Mexico, Greece, Puerto Rico, Gu... and more
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
Sanofi

Terminated

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (TRENT)

Type 2 Diabetes Mellitus | Renal Impairment

United States, Czechia, Hungary, Poland, Serbia
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Eli Lilly and Company

Completed

Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (IOOX)

Diabetes Mellitus, Type 2

Australia, Russian Federation, Spain, Mexico, Canada, France, Korea, Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Malaysia, Thailand, China, Philippines
Shanghai Jiao Tong University School of Medicine

Unknown

Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Type 2 Diabetes

China
Eli Lilly and Company

Completed

A Study of LY2963016 in Healthy Participants

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Diabetes Mellitus

Singapore
Sanofi

Completed

Glycemic Optimization Treatment Study (GOT)

Diabetes Mellitus, Type 2
Sanofi

Completed

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients (LanScape)

Diabetes Mellitus, Type 2

Australia, United Kingdom
Eli Lilly and Company

Terminated

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (HMH)

Hyperglycemia

United States
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
Amsterdam UMC, location VUmc

Completed

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes (LIBRA)

Obesity | Type 2 Diabetes

Netherlands
Charles Drew University of Medicine and Science
National Center for Research Resources (NCRR)

Completed

Insulin Glargine at Bedtime or in AM Versus NPH

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey

3

Subscribe